PRGO (Perrigo) Future Price to Earnings
Margin risks for Perrigo Company plc (PRGO) are driven by fierce competition in the private label segment and logistical disruptions. The change in the company's forward P/E multiple visualizes these factors, where the parameter value equals 7.20. Business resilience is supported by diversification into hygiene products and baby food. Management's current focus on asset optimization facilitates a long-term recovery in profitability.
Summary analytical data breakdowns for Perrigo Corp (PRGO)
- current price and projected stock value:
- business market valuation indicators:
- balance sheet equity data:
- debt level and financial liquidity data:
Total Debt to Capital Perrigo Company plc|PRGO - Long-Term Liabilities to Capital|Short-Term Debt to Equity Perrigo Company plc|PRGO - Aggregate Debt Obligations|Debt to Book Capitalization Ratio Perrigo Company PLC|PRGO - Long-Term Liabilities|Company Short-Term Debts Perrigo|Quick Liquidity perrigo.com
- financial results and valuation multiples details:
PRGO - Final Profit|Expected Profit Perrigo Company plc|PRGO - Company Value to Net Income|Forward P/E Multiple Perrigo Company|PRGO - Growth-Adjusted Market Cap to Net Income|EV/EBITDA Multiple Perrigo Company PLC|PRGO - Operating profit before depreciation charges|Earnings per share for the last twelve months Perrigo|PRGO - Net earnings per one share for the last twelve months|Year-over-year net earnings per share growth for the last 12 months perrigo.com|PRGO - Earnings per share increase in current year|Earnings growth forecast for next year Perrigo Company plc
Fundamental valuation:PRGO Perrigo
To minimize long-term capital risks, it is essential to avoid overvalued assets where an inflated multiple foreshadows a correction. By analyzing the company's consensus P/E forecast, an investor compares the current share price with expected earnings, which for the OTC market leader Perrigo Company plc (PRGO) reflects the efficiency of generic scaling and margin stability across global distribution, ultimately determining the business's investment attractiveness.
Competitor analysis for Perrigo Company plc
Projected Price to Earnings HLN (Haleon)|KVUE (Kenvue Inc) - Future Price to Earnings Multiple|Future Price to Earnings Verona Pharma Corp VRNA|Jyong Bio (MENS) - Projected Price to Earnings Ratio|LGND: Projected Price to Earnings|amneal.com - Market Cap to Future Earnings Ratio|ALVO: Forward P/E Multiple|Liquidia Corp - Future Price to Earnings Multiple|GLPG (Galapagos Genomics) - Forward P/E Multiple|Projected Price to Earnings Ratio ANI Pharmaceuticals Corp ANIP|Future Price to Earnings MannKind Corporation (MNKD)|AMPH (amphastar.com) - Future Price to Earnings Multiple|Future Price to Earnings Pacira BioSciences, Inc. PCRX|SPRY (ARS Pharmaceuticals Inc) - Price to Expected Earnings Ratio|Theravance - Forward P/E Multiple|Projected Price to Earnings Ratio Aquestive Corp|scpharmaceuticals.com (SCPH) - Future Price to Earnings|Tectonic Therapeutic - Future Price to Earnings Multiple|Future Price to Earnings Tonix Pharmaceuticals Holding Corp.|SXTC: Future Price to Earnings Multiple|Forward P/E Multiple EPRX|Market Cap to Projected Earnings BioHarvest Sciences Inc|Forward P/E Multiple EXOZ (eXoZymes Inc)|Forward Price to Earnings Multiple Oramed|ENTX - Future Price to Earnings|Projected Price to Earnings Ratio MindWalk Holdings, Inc.|ABVC (ABVC BioPharma Inc) - Projected Price to Earnings|Cumberland Corp - Future Price to Earnings Multiple|QNTM (Quantum BioPharma Ltd) - Forward P/E Multiple|Projected Price to Earnings fibrogen.com (FGEN)|Future Price to Earnings Telomir Pharmaceuticals, Inc. (TELO)|RANI - Projected Price to Earnings Ratio|Future Price to Earnings Synergy CHC SNYR|RLYB - Projected Price to Earnings|LEXX - Future Price to Earnings|Price to Expected Earnings Ratio PULM|PTHL: Forward P/E Multiple|Aptorum Group (APM) - Forward P/E Multiple|Future Price to Earnings Lyra Therapeutics, Inc|Price to Future Earnings Ratio IBO (Impact BioMedical, Inc.)|Projected Price to Earnings TNFA (TNF Pharmaceuticals)|YCBD - Projected Price to Earnings Ratio|PainReform - Projected Price to Earnings|Future Price to Earnings Multiple CYTO|LIPO - Future Price to Earnings|Price to Expected Earnings Ratio OPTN|Pieris Pharmaceuticals (PIRS) - Future Price to Earnings|PROC (procapsgroup.com) - Future Price to Earnings|PTPI (Petros Pharmaceuticals, Inc.) - Forward P/E Multiple|Projected Price to Earnings Qilian International Holding Group (QLI)|Future Price to Earnings ACELYRIN, Inc. (SLRN)|TFFP: Price to Expected Earnings Ratio
